SRRK vs. RGNX, CCCC, CHRS, CPRX, SWTX, APGE, IOVA, ACLX, DNLI, and TWST
Should you be buying Scholar Rock stock or one of its competitors? The main competitors of Scholar Rock include REGENXBIO (RGNX), C4 Therapeutics (CCCC), Coherus BioSciences (CHRS), Catalyst Pharmaceuticals (CPRX), SpringWorks Therapeutics (SWTX), Apogee Therapeutics (APGE), Iovance Biotherapeutics (IOVA), Arcellx (ACLX), Denali Therapeutics (DNLI), and Twist Bioscience (TWST). These companies are all part of the "medical" sector.
REGENXBIO (NASDAQ:RGNX) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, community ranking, risk, analyst recommendations, earnings, dividends and profitability.
In the previous week, REGENXBIO and REGENXBIO both had 5 articles in the media. Scholar Rock's average media sentiment score of 0.69 beat REGENXBIO's score of 0.48 indicating that REGENXBIO is being referred to more favorably in the media.
88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 13.1% of REGENXBIO shares are owned by company insiders. Comparatively, 26.2% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Scholar Rock has lower revenue, but higher earnings than REGENXBIO. Scholar Rock is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
REGENXBIO has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
REGENXBIO received 275 more outperform votes than Scholar Rock when rated by MarketBeat users. Likewise, 65.74% of users gave REGENXBIO an outperform vote while only 63.40% of users gave Scholar Rock an outperform vote.
REGENXBIO presently has a consensus price target of $38.64, indicating a potential upside of 169.24%. Scholar Rock has a consensus price target of $25.17, indicating a potential upside of 168.02%. Given Scholar Rock's higher probable upside, equities research analysts clearly believe REGENXBIO is more favorable than Scholar Rock.
Scholar Rock has a net margin of 0.00% compared to Scholar Rock's net margin of -299.96%. Scholar Rock's return on equity of -70.72% beat REGENXBIO's return on equity.
Summary
REGENXBIO beats Scholar Rock on 10 of the 18 factors compared between the two stocks.
Get Scholar Rock News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scholar Rock Competitors List
Related Companies and Tools
